Article 4B.
Pharmacy Quality Assurance Protection Act.

§ 90-85.45. Legislative intent.
It is the intent of the General Assembly to require pharmacy quality assurance programs to further contribute to and enhance the quality of health care and reduce medication errors in this State by facilitating a process for the continuous review of the practice of pharmacy. (2005-427, s. 3.)

§ 90-85.46. Definitions.
The following definitions shall apply in this Article:

(1) Board. – The North Carolina Board of Pharmacy.

(2) Pharmacy quality assurance program. – A program pertaining to one of the following:
   a. A pharmacy association created under G.S. 90-85.4 or incorporated under Chapter 55A of the General Statutes that evaluates the quality of pharmacy services and alleged medication errors and incidents and makes recommendations to improve the quality of pharmacy services.
   b. A program established by a person or entity holding a valid pharmacy permit pursuant to G.S. 90-85.21 or G.S. 90-85.21A to evaluate the quality of pharmacy services and alleged medication errors and incidents and make recommendations to improve the quality of pharmacy services.
   c. A quality assurance committee or medical or peer review committee established by a health care provider licensed under this Chapter or a health care facility licensed under Chapter 122C, 131D, or 131E of the General Statutes that includes evaluation of the quality of pharmacy services and alleged medication errors and incidents and makes recommendations to improve the quality of pharmacy services. (2005-427, s. 3; 2006-259, s. 16(a).)

§ 90-85.47. Pharmacy quality assurance program required; limited liability; discovery.

(a) Every person or entity holding a valid pharmacy permit pursuant to G.S. 90-85.21 or G.S. 90-85.21A shall establish or participate in a pharmacy quality assurance program as defined under G.S. 90-85.46(2), to evaluate the following:
   (1) The quality of the practice of pharmacy.
   (2) The cause of alleged medication errors and incidents.
   (3) Pharmaceutical care outcomes.
   (4) Possible improvements for the practice of pharmacy.
   (5) Methods to reduce alleged medication errors and incidents.

(b) There shall be no monetary liability on the part of, or no cause of action for damages arising against, any member of a duly appointed pharmacy quality assurance program or any pharmacy or pharmacist furnishing information to a pharmacy quality assurance program or any person, including a person acting as a witness or incident reporter to or investigator for a pharmacy
quality assurance program, for any act or proceeding undertaken or performed within the scope of
the functions of the pharmacy quality assurance program.

(c) This section shall not be construed to confer immunity from liability on any
professional association, pharmacy or pharmacist, or health care provider while performing
services other than as a member of a pharmacy quality assurance program or upon any person,
including a person acting as a witness or incident reporter to or investigator for a pharmacy quality
assurance program, for any act or proceeding undertaken or performed outside the scope of the
functions of the pharmacy quality assurance program. Except as provided in subsection (a) or (b)
of this section, where a cause of action would arise against a pharmacy, pharmacist, or an
individual health care provider, the cause of action shall remain in effect.

(d) The proceedings of a pharmacy quality assurance program, the records and materials it
produces, and the materials it considers shall be confidential and not considered public records
within the meaning of G.S. 132-1 or G.S. 58-2-100 and shall not be subject to discovery or
introduction into evidence in any civil action, administrative hearing or Board investigation against
a pharmacy, pharmacist, pharmacy technician, a pharmacist manager or a permittee or a hospital
licensed under Chapter 122C or Chapter 131E of the General Statutes or that is owned or operated
by the State, which civil action, administrative hearing or Board Investigation results from matters
that are the subject of evaluation and review by the pharmacy quality assurance program. No
person who was in attendance at a meeting of the pharmacy quality assurance program shall be
required to testify in any civil action, administrative hearing or Board investigation as to any
evidence or other matters produced or presented during the proceedings of the pharmacy quality
assurance program or as to any findings, recommendations, evaluations, opinions, or other actions
of the pharmacy quality assurance program or its members. However, information, documents, or
records otherwise available are not immune from discovery or use in a civil action merely because
they were presented during proceedings of the pharmacy quality assurance program. Documents
otherwise available as public records within the meaning of G.S. 132-1 do not lose their status as
public records merely because they were presented or considered during proceedings of the
pharmacy quality assurance program. A member of the pharmacy quality assurance program may
testify in a civil or administrative action but cannot be asked about the person's testimony before
the pharmacy quality assurance program or any opinions formed as a result of the pharmacy quality
assurance program. Nothing in this subsection shall preclude:

(1) A pharmacy, pharmacist, pharmacy technician, or other person or any agent or
representative of a pharmacy, pharmacist, pharmacy technician or other person
participating on a pharmacy quality assurance program may use otherwise
privileged, confidential information for legitimate internal business or
professional purposes of the pharmacy quality assurance program.

(2) A pharmacy, pharmacist, pharmacy technician, other person participating on
the committee, or any person or organization named as a defendant in a civil
action, a respondent in an administrative proceeding, or a pharmacy,
pharmacist, or pharmacy technician subject to a Board investigation as a result
of participation in the pharmacy quality assurance program may use otherwise
privileged, confidential information in the pharmacy quality assurance program
or person's own defense. A plaintiff in the civil action or the agency in the
administrative proceeding may disclose records or determinations of or
communications to the pharmacy quality assurance program in rebuttal to
information given by the defendant, respondent, or pharmacist subject to Board investigation.

(e) Upon the Board providing written notice to the pharmacy permittee's designated agent under G.S. 90-85.21(a) and pharmacist of an investigation against the pharmacist, including the specific reason for the Board investigation, the pharmacy permittee's designated agent shall compile and provide documentation within 10 days of the receipt of the notice of any alleged medication error or incident committed by the pharmacist in the 12 months preceding the receipt of the notice, that the pharmacy permittee has knowledge of, when:

1. The alleged medication error or incident resulted in any of the following:
   a. A visit to a physician or an emergency room attributed to the alleged medication incident or error.
   b. Hospitalization requiring an overnight stay or longer.
   c. A fatality.

2. The Board has initiated a disciplinary proceeding against the pharmacist as a result of the investigation. Unless the documentation relates to an alleged medication error or incident that was specifically the cause of the investigation, the Board may review the documentation only after the Board has made findings of fact and conclusions of law pursuant to G.S. 150B-42(a) and may use the documentation in determining the remedial action the pharmacist shall undergo as part of the disciplinary action imposed by the Board. The documentation shall be released only to the Board or its designated employees pursuant to this subsection and shall not otherwise be released except as required by law.

The documentation provided to the Board shall not include the proceedings and records of a pharmacy quality assurance program or information prepared by the pharmacy solely for consideration by or upon request of a pharmacy quality assurance program.

(f) Nothing in this section shall preclude the Board from obtaining information concerning a specific alleged medication error or incident that is the subject of a Board investigation resulting from a complaint to the Board. (2005-427, s. 3; 2006-259, s. 16(b).)

§ 90-85.48: Reserved for future codification purposes.

§ 90-85.49: Reserved for future codification purposes.